02 June 2020
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group announce that Avifavir has received a temporary registration certificate from the Ministry of Health of the Russian Federation. Avifavir is Russia’s first COVID-19 drug and has shown high efficacy in treating patients with coronavirus during clinical trials.
Online press conference with details about Avifavir will be held on June 1 at 10:00 Moscow time.
Avifavir, which disrupts the reproduction mechanisms of coronavirus, is the first Russian direct antiviral drug that has proven effective in clinical trials. The drug has been well studied, since it has been used in Japan since 2014 against severe forms of influenza.
The intermediate data of Avifavir clinical trials confirm its high efficacy against COVID-19. The final stage of Avifavir clinical trials involving 330 patients, approved by the Russian Ministry of Health on May 21, 2020, is ongoing.
The drug proved to be highly effective during the clinical trials involving I.M. Sechenov First Moscow State Medical University, Lomonosov Moscow State University and other medical and academic institutions.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund
Afivavir is not only the first antiviral drug registered against coronavirus in Russia, but it is also perhaps the most promising anti-COVID-19 drug in the world. It was developed and tested in clinical trials in Russia in unprecedentedly short period of time enabling Afivavir to become the first registered drug based on Favipiravir in the world.
09 July 2020
08 July 2020
08 July 2020
07 July 2020